安旭生物1月22日获融资买入364.12万元，融资余额1.07亿元

Group 1 - The core viewpoint of the news is that Anxu Bio experienced a decline in stock price and significant changes in financing activities on January 22, with a net financing buy of -358.91 million yuan [1] - On January 22, Anxu Bio's stock price fell by 0.46%, with a trading volume of 33.73 million yuan, and the total financing and securities lending balance reached 107 million yuan [1] - The financing buy amount for Anxu Bio on that day was 3.64 million yuan, while the financing repayment was 7.23 million yuan, indicating a high financing balance relative to its market value [1] Group 2 - As of September 30, Anxu Bio had 6,090 shareholders, an increase of 1.10% from the previous period, while the average circulating shares per person decreased by 1.08% to 20,867 shares [2] - For the period from January to September 2025, Anxu Bio reported a revenue of 325 million yuan, a year-on-year decrease of 19.34%, and a net profit attributable to shareholders of 64.36 million yuan, down 52.60% year-on-year [2] - Anxu Bio has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2]